Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene

Anticancer Research

Volumn 17, Issue 2 A, 1997, Pages 879-883

  Kimura, Masaki ^a,b   Tagawa, Masatoshi ^a,b   Takenaga, Keizo ^b   Yamaguchi, Taketo ^a   Saisho, Hiromitsu ^a   Nakagawara, Akira ^b   Sakiyama, Shigeru ^b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA CANCER CENTER   (Japan)

Author keywords

Chemosensitivity; p53; Pancreatic tumor; Retrovirus

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL GROWTH; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; CELL DIVISION; GENE THERAPY; GENES, P53; HUMANS; MICE; MICE, INBRED BALB C; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0030974567     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Grünewald K, Lyons J, Fröhlich A, Feichtinger H, Wcger RA, Schwab G, Janssen JWG and Bartram CR: High frequency of K-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 43: 1037-1041, 1989.
2. Hall PA, Hughes CM, Staddon SL, Richman PI, Gullick WJ and Lemoine NR: The c-erbB-2 proto-oncogene in human pancreatic cancer. J Path 161: 195-200, 1990.
3. Lane DP: p53, guardian of the genome. Nature 358: 15-16, 1992.
4. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
5. Berrozpe G, Schaeffer J, Peinado MA, Real FX and Pcrucho M: Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer 58: 185-191, 1994.
6. Lowe SW, Ruley HE, Jacks T and Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957-967, 1993.
7. Aas T, Børresen A-L, Geisler S, Smith-Søresen Johnsen H, Varhaug JE, Akslen L and Laming PE: Specific p53 mutations are associated with de novo resistance to doxorubiein in breast cancer patients. Nature Med 2: 811-814, 1996.
8. Baker SJ, Markowitz S, Fearon ER, Willson JKV and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915, 1990.
9. Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T and Roth JA: Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediaied gene transfer. Hum Gene Ther 4: 617-624, 1993.
10. Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R and Minna JD: Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52: 2340-2343, 1992.
11. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA and Roth JA: Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86: 1458-1462, 1994.
12. Chen WH, Horoszcwicz JS, Leong SS, Shimano T, Penetrante R, Sanders WH, Berjian R, Douglass HO, Martin EW and Chu TM: Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In Vitro 18: 24-34, 1982.
13. Miller AD and Rosman GJ: Improved retroviral vectors for gene transfer and expression. BioTechniques 7: 980-990, 1989.
14. Tsai S-CL, Gansbacher B, Tait L, Miller FR, Heppncr GH: Induction of amitiimor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibrobtiists. J Natl Cancer Inst 55: 546-553, 1993.
15. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD and KleinSzanto AJP: Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumorsuppressor genes. Oncogene 7: 1503-1511, 1992.
16. Jacks T and Wciberg RA: Cell-cycle control and its watchman. Nature 381: 643-644, 1996.
17. Hawkins DS, Demers GW and Galloway DA: Inaclivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56: 892-898, 1996.
18. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, OwenSchaub LB and Roth JA: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wildtype p53 gene. Cancer Res 54: 2287-2291, 1994.
19. Percgo P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
20. Liebermann DA, Huffman B and Steinman RA: Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene 11: 199-210, 1995.
21. Hayashi Y, Yamashita J and Yamaguchi K: Timing and role of p53 gene mutation in the recurrence of glioma. Biochem Biophys Res Commun 180: 1145-1150, 1991.
22. Felix CA, Nau MM, Takahashi T, Misudomi T, Chiba I, Poplack DG, Reaman GH, Cole DE, Letterio JJ, Whang-Peng J, Knutsen T and Minna JD: Hereditary and acquired p53 gene mutations in childhood acute lymphoblastic leukemia. J Clin Invest 89: 640-647, 1992.
23. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA: Loss of p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79, 1996.
24. Delia D, Mizutani S, Lamorte G, Goi K, Iwata T and Pierotti MA: p53 activity and chemotherapy. Nature Med 2: 724-725, 1996.
25. Bradley G, Juranka PF and Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
26. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
27. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wildtype p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 ullels. Cell 70: 937-948, 1992.
28. Iwadate Y, Fujimoto S, Tagawa M, Namba H, Sueyoshi K, Hirose M and Sakiyama S: Association of p53 gene mutation with decreased chemosensitivity in human malignant gliomas. Int J Cancer 60: 236240, 1996.
29. Roth JA, Nguycn D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KMW, Putnan JB, Schea R, Shin DM, Walsh GL, Dolormente MM, Han C-I, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T and Cai D: Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 2: 985-991, 1996.